Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

In a nutshell, Amgen claimed other parties could easily use its patents as a roadmap to develop PCSK9 antibodies, without having to carry out a lot of additional testing. Sanofi and Regeneron ...

FDA approval wasn’t an easy ride, as protracted patent wrangles ... in 2004, and monoclonal antibody Vectibix approved for colon cancer in 2006. "A key part of Amgen’s strategy was to broaden ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

The potential entry of Amgen’s Pavblu poses a threat to EYLEA ... lung cancer and other solid tumors, biospecific antibodies for blood cancers, and Factor XI antibodies for blood clot prevention ...

Opens in a new tab or window An investigational monoclonal antibody targeting interferon ... Akari, Alexion, Amgen, ANI Pharmaceuticals, Argenx, AstraZeneca, Bayer, Beacon Bioscience, Biogen ...

Tislelizumab is a monoclonal antibody with high affinity and specificity ... It has maximized cooling efficiency by utilizing patented air circulation technology based on a natural convection ...